RXRX RECURSION PHARMACEUTICALS INC

Recursion to Participate in Upcoming Investor Conferences

Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences:

  • Guggenheim 2nd Annual Healthcare Innovation Conference — Tuesday, November 11, 2025
  • Jefferies Global Healthcare Conference London — Tuesday, November 18, 2025

Webcasts may be found in the events section of the Recursion Investor Relations website at .

About Recursion

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area. Learn more at , or connect on and .



Investor Contact
 

Media Contact
 
EN
04/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RECURSION PHARMACEUTICALS INC

 PRESS RELEASE

Recursion Reports Third Quarter 2025 Financial Results and Provides Bu...

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of neurological diseasesWith this achievement, Recursion will have reached over $500 million in milestone and upfront payments across all its partnerships and collaborationsApproximately $785 million of cash and cash equivalents (unaudited) as of October 9, 2025- runway through the end of 2027, without additional financing...

 PRESS RELEASE

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board of Directors has unanimously approved a leadership transition plan to become effective January 1, 2026: Najat Khan, Ph.D., currently Chief R&D and Commercial Officer and a Board Member...

 PRESS RELEASE

Recursion to Participate in Upcoming Investor Conferences

Recursion to Participate in Upcoming Investor Conferences Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference — Tuesday, November 11, 2025 Jefferies Global Healthcare Conference London — Tuesday, November 18, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at .About RecursionRecursion (NASDA...

 PRESS RELEASE

Recursion to Report Third Quarter 2025 Business Updates and Financial ...

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 financial results on Wednesday, November 5, 2025, before the open of the financial markets.Recursion will host a (L)earnings Call on November 5, 2025 at ...

 PRESS RELEASE

Recursion to Participate in Upcoming Investor Conferences

Recursion to Participate in Upcoming Investor Conferences Salt Lake City, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Citi 2025 BioPharma Back to School Conference — Wednesday, September 3, 2025 Morgan Stanley 23rd Annual Global Healthcare Conference — Monday, September 8, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at .About RecursionRecursion (NAS...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch